Breast Cancer, Camrelizumab, Triple Negative Breast Cancer
Conditions
Keywords
Triple Negative Breast Cancer, Camrelizumab, Neoadjuvant chemotherapy, Pathological complete response rate, Disease-free survival
Brief summary
Triple-negative breast cancer (TNBC) is a special subtype of breast cancer that lacks the expression of ER, PR, and Her-2 proteins, accounting for 15%-20% of all breast cancers.TNBC patients do not benefit from endocrine therapy or HER-2-targeted therapy, but are sensitive to cytotoxic drug therapy.Although the survival of TNBC patients has improved significantly compared with the past, it is still the type with the worst prognosis among all subtypes of breast cancer. Methods and drugs to further improve the therapeutic effect of TNBC patients are still being explored. Camrelizumab, a PD-1 inhibitor produced by Hengrui, has been approved for the treatment of various malignant tumors including advanced lung cancer, advanced liver cancer and advanced esophageal cancer. Shows good therapeutic effect and safety. Therefore, this study intends to explore the superiority of camrelizumab on the basis of the less toxic anthracycline-free TCb regimen.In order to provide more effective and safe neoadjuvant therapy for lymph node-positive TNBC patients.
Detailed description
This study mainly compared the efficacy and safety of 6\*TCb (docetaxel+carboplatin)+carrelizumab regimen and 6\*TCb regimen in neoadjuvant chemotherapy for triple-negative breast cancer. Patients who met the inclusion criteria were randomly assigned to the experimental group and the control group in a 2:1 ratio. * The experimental group received 6 cycles of TCb+carrelizumab (docetaxel 75mg/m2 on the first day + carboplatin AUC=6, on the first day; camrelizumab 200mg on the third day) regimen neoadjuvant chemotherapy, every 21 days is a cycle. * The control group received 6 cycles of TCb (docetaxel 75mg/m2 on the first day + carboplatin AUC=6 on the first day) regimen neoadjuvant chemotherapy, every 21 days as a cycle. The efficacy and safety of the two chemotherapy regimens on neoadjuvant chemotherapy for triple-negative breast cancer were evaluated by PCR, EFS, DFS, DDFS and ORR after surgery.
Interventions
DRUG（Carrelizumab + TCb） regimen
Carrelizumab +docetaxel + carboplatin regimen
DRUGTCb regimen
docetaxel + carboplatin regimen
Sponsors
Zhenzhen Liu
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The enrolled patients were randomly assigned to the experimental group and the control group in a ratio of 2:1.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Age: 18-70 years old 2. cT2 - cT4d, or cT1c with axillary lymph node metastasis confirmed clinically and pathologically； 3. Pathologically proven triple negative breast cancer: Triple-negative breast cancer is defined as: * Negative for ER and PR (IHC nuclear staining \<10%) * Her-2 negative (IHC 0, 1+ without FISH, or IHC 2+ with no amplification by FISH)； 4. Has clinically measurable lesions:Measurable lesions on ultrasound, mammography, or MR (optional) within 1 month before randomization； 5. Organ and bone marrow function tests within 1 month before chemotherapy suggest no contraindications to chemotherapy； 6. Cardiac ultrasound EF value ≧55%； 7. Females of childbearing age, with a negative serum pregnancy test 14 days before randomization; 8. ECOG score≤1 point; 9. Sign informed consent；
Exclusion criteria
1. The patient has evidence of metastatic breast cancer； 2. For this disease, chemotherapy, endocrine therapy, targeted therapy, radiation therapy, etc. have been received; 3. The patient has a second primary malignancy other than adequately treated skin cancer; 4. The patient has been treated with anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death ligand 1 (anti-PD-L1) or anti-PD-L2 drugs, or other immunotherapy； 5. The patient has been diagnosed with immunodeficiency disease or autoimmune disease; 6. The patient has severe lung or heart disease; 7. The patient has active hepatitis B and C; 8. The patient has a history of organ transplantation or bone marrow transplantation; 9. pregnant or breastfeeding women; 10. The investigators considered chemotherapy contraindicated due to serious, uncontrolled other medical conditions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathological complete response rate (pCR rate) | up to 24 weeks | After neoadjuvant chemotherapy and surgery, the resected specimen (breast + axilla) was free of any invasive cancer (ie, ypT0/is, ypN0) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Event-Free Survival (EFS) | 5-10 years after surgery. | EFS was defined as the time from randomization to any of the following events: disease progression during neoadjuvant therapy, local or distant recurrence, second primary malignancy (breast or other cancer), or death from any cause. |
| DFS | 5-10 years after surgery | Disease-free Survival,From the date of surgery to the first local, regional, contralateral or distant recurrence, and death from any cause |
| Distant Disease Free Survival (DDFS) | 5-10 years after surgery | DDFS is defined as the time from surgery to distant recurrence or death from any cause |
| Objective Response Rate (ORR) | Preoperative | ORR is defined as the number of target lesion responders as assessed by MRI |
| number of adverse events | After each cycle of chemotherapy (21 days as 1 cycle) | Evaluate the nature, incidence and severity of chemotherapy adverse events according to CTCAE 5.0 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Expression of PD-L1 | up to 24 weeks | Differences in the benefits of carelizumab under different PD-L1 expression status |
| gene mutation rate | up to 24 weeks | Predictive value of polygenic analysis in the population benefiting from camrelizumab |
Countries
China
Contacts
Primary ContactZhenzhen Liu
Backup ContactDechuang Jiao
Outcome results
None listed